Medgenics is currently focused on developing its Biopump platform for anemia (EPODURE, producing erythropoietin (EPO)) and hepatitis C (INFRADURE, which produces interferon-alpha (IFN-α)).

EPODURE is scheduled to enter Phase I/II efficacy trials in mid-2008. Clinical trials with INFRADURE are planned to follow.

Medium term applications to be pursued also include multiple sclerosis, hemophilia and pediatric growth hormone deficiency/muscular atrophy.

In addition, the Company’s platform technology has the potential to treat a range of other therapeutic areas such as diabetes, arthritis, wound healing, obesity, chronic pain and cancer recovery.